Cancers (blood cancers)


This information is intended for HCP only. This is a prescription based drug. Please consult your doctor if you need more information.

Polatuzumab vedotin is a CD79b-targeted antibody-drug conjugate that preferentially delivers a potent anti-mitotic agent (monomethyl auristatin E, or MMAE) to B-cells, which results in the killing of malignant B-cells.  Polivy is approved for the treatment of adult patients with previously untreated diffuse large B-cell lymphoma, and adult patients with relapsed/refractory diffuse large B-cell lymphoma who are not candidates for haematopoietic stem cell transplant.

In case of any adverse events or safety queries, please contact:

If you have a scientific query related to one of Roche's products, please contact:


This website contains information on products which is targeted to a wide range of audiences and could contain product details or information otherwise not accessible or valid in your country.Please be aware that we do not take any responsibility for accessing such information which may not comply with any valid legal process, regulation, registration or usage in the country of your origin.

ContactLocationslinkedinfacebooktwitterinstagramyoutubeAbout RochePharma solutionsRoche careersPrivacy StatementLegal Statement